Keywords
Anxiety Disorders ×
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
Selected data models

You must log in to select data models for download or further analysis.

- 6/25/20 - 1 form, 2 itemgroups, 34 items, 1 language
Itemgroups: Administrative data, SOCIAL ANXIETY QUESTIONNAIRE FOR ADULTS
Caballo, V. E., Salazar, I. C., Irurtia, M. J., Arias, B., and CISO-A Research Team. (2012) . Social Anxiety Questionnaire for Adults (SAQ-A30) . Measurement Instrument Database for the Social Science. Retrieved 25.06.2020 from www.midss.ie Key references: Caballo, V. E., Salazar, I. C., Arias, B., Irurtia, M. J., Calderero, M., & the CISO-A Research Team Spain (2010a). Validation of the Social Anxiety Questionnaire for Adults (SAQ-A30) with Spanish university students: Similarities and differences among degree subjects and regions. Behavioral Psychology/ Psicologia Conductual, 18, 5–34. Caballo, V. E., Salazar, I. C., Irurtia, M. J., Arias, B., Hofmann, S. G., & the CISO-A Research Team (2010b). Measuring social anxiety in 11 countries: Development and validation of the Social Anxiety Questionnaire for Adults. European Journal of Psychological Assessment, 26, 95–107. Caballo, V. E., Salazar, I. C., Irurtia, M. J., Arias, B., Hofmann, S. G. & CISO-A Research Team (2012). The multidimensional nature and multicultural validity of a new measure of social anxiety: the Social Anxiety Questionnaire for Adults. Behavior Therapy, 43, 313-328. Primary use / Purpose: The questionnaire is designed to measure specific and/or generalized social phobia/anxiety in adults (18 years and more) from general and clinical populations. This is very useful for identifying not only people with generalized social phobia but particularly specific social phobia. Background: The Social Anxiety Questionnaire for Adults (SAQ-A30) was a result of several years of work by the research team in 18 Latin American countries, Spain, and Portugal. It was developed from research with approximately 58,000 general participants and more than 1,000 social phobic patients. Regarding initial item selection, more than 1,000 participants recorded situations over 6 years, generating a pool of more than 10,000 social situations. From these, two pairs of social anxiety experts selected scenarios for initial analysis, excluding those situations that were redundant or were not social in nature (i.e., another person[s] played a role in the situation). This left 2,171 scenarios, which were then grouped together based on substantive similarity, leaving a total of 512 social situations. These situations composed the first version of the SAQ-A and after many statistical analyses and clinical judgments, the final version of the 30-item questionnaire was obtained (SAQ-A30). Psychometrics: The SAQ-A30 contains 30 items conforming a social phobia/anxiety structure of five very solid dimensions (factors), each of them including six items. Each dimension has its own cut-off score as the questionnaire also has as a whole. Data on the questionnaire's internal consistency, construct validity, cut-off scores, invariance, and factor structure have been presented (Caballo et al., 2010a, 2012). Other Information: Each item is answered on a 5-point Likert scale. The higher the score in every dimension the more anxiety the person has in this specific dimension. The sum of all the dimensions is the general score of the questionnaire. The five dimensions are the following: 1) Speaking in public/talking with people in authority, 2) Interactions with the opposite sex, 3) Assertive expression of annoyance, disgust, or displeasure, 4) Criticism and embarrassment, and 5) Interactions with strangers. The original questionnaire plus two control items and the cut-off scores for each factor and for the whole questionnaire are included in the reference below: Caballo, V. E., Salazar, I. C., Irurtia, M. J., Arias, B., Hofmann, S. G. & CISO-A Research Team (2012). The multidimensional nature and multicultural validity of a new measure of social anxiety: the Social Anxiety Questionnaire for Adults. Behavior Therapy, 43, 313-328. The original questionnaire without the control items is included in the following reference: Caballo, V. E., Salazar, I. C., Arias, B., Irurtia, M. J., Calderero, M., & the CISO-A Research Team Spain (2010a). Validation of the Social Anxiety Questionnaire for Adults (SAQ-A30) with Spanish university students: Similarities and differences among degree subjects and regions. Behavioral Psychology/ Psicologia Conductual, 18, 5–34. Initial development and validation of previous versions of the questionnaire can be found in the following reference: Caballo, V. E., Salazar, I. C., Irurtia, M. J., Arias, B., Hofmann, S. G., & the CISO-A Research Team (2010b). Measuring social anxiety in 11 countries: Development and validation of the Social Anxiety Questionnaire for Adults. European Journal of Psychological Assessment, 26, 95–107. P.D.: Although we have tried not to include situations related to the gender of people in the questionnaire, there are three items that include the term “opposite sex”. There was no way to substitute them. We suggest that for people whose sexual tendency is their same gender to substitute “opposite sex” for “preferred gender”. Copyright by Fundacion VECA. The questionnaire can be used for research and clinical purposes without further permission. However it can not be modified, used commercially or published by any means without prior permission from the first author (in the name of Fundacion VECA). Digital Object Identifier (DOI): http://dx.doi.org/10.13072/midss.223
- 1/17/24 - 5 forms, 1 itemgroup, 20 items, 1 language
Itemgroup: pht005195
Principal Investigator: Barbara K. Lipska, PhD, National Institutes of Health, Bethesda, MD, USA MeSH: Schizophrenia,Anxiety Disorders,Autism Spectrum Disorder,Bipolar Disorder,Control Groups,Feeding and Eating Disorders,Depressive Disorder, Major,Obsessive-Compulsive Disorder,Stress Disorders, Post-Traumatic,Tic Disorders,Williams Syndrome https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000979 This postmortem study examines molecular, genetic and epigenetic signatures in the brains of hundreds of subjects with or without mental disorders conducted by the DIRP NIMH Human Brain Collection Core (HBCC). The brain tissues are obtained under protocols approved by the CNS IRB (NCT00001260), with the permission of the next-of-kin (NOK) through the Offices of the Chief Medical Examiners (MEOs) in the District of Columbia, Northern Virginia and Central Virginia. Additional samples were obtained from the University of Maryland Brain and Tissue Bank (contracts NO1-HD-4-3368 and NO1-HD-4-3383) (http://www.medschool.umaryland.edu/btbank/ and the Stanley Medical Research Institute (http://www.stanleyresearch.org/brain-research/). Clinical characterization, neuropathological screening, toxicological analyses, and dissections of various brain regions were performed as previously described (Lipska et al. 2006; PMID: 16997002). All patients met DSM-IV criteria for a lifetime Axis I diagnosis of psychiatric disorders including schizophrenia or schizoaffective disorder, bipolar disorder and major depression. Controls had no history of psychiatric diagnoses or addictions. *SNP array:* Array-based genotyping was performed on most samples published in this collection. The number of SNPs assayed via Illumina chips varied between 650,000 and 5 Million. Cerebellar tissue was generally used for genotyping studies. table width="481" border="1" tbody tr td width="64" align="center" strong#/strong /td td width="275" strongDiagnosis/strong /td td width="57" align="center" strongSNP Array/strong /td /tr tr td width="64" align="center"1/td td width="275"Anxiety Disorder/td td width="57" align="center"1/td /tr tr td width="64" align="center"2/td td width="275"Autism Spectrum Disorder/td td width="57" align="center"13/td /tr tr td width="64" align="center"3/td td width="275"Bipolar Disorder/td td width="57" align="center"114/td /tr tr td width="64" align="center"4/td td width="275"Control/td td width="57" align="center"387/td /tr tr td width="64" align="center"5/td td width="275"Eating Disorder (ED)/td td width="57" align="center"2/td /tr tr td width="64" align="center"6/td td width="275"Major Depressive Disorder (MDD)/td td width="57" align="center"186/td /tr tr td width="64" align="center"7/td td width="275"Obsessive Compulsive Disorder (OCD)/td td width="57" align="center"5/td /tr tr td width="64" align="center"8/td td width="275"Post-Traumatic Stress Disorder (PTSD)/td td width="57" align="center"0/td /tr tr td width="64" align="center"9/td td width="275"Schizophrenia/td td width="57" align="center"220/td /tr tr td width="64" align="center"10/td td width="275"Other/td td width="57" align="center"7/td /tr tr td width="64" align="center"11/td td width="275"Tic Disorder/td td width="57" align="center"3/td /tr tr td width="64" align="center"12/td td width="275"Undetermined/td td width="57" align="center"1/td /tr tr td width="64" align="center"13/td td width="275"Williams Syndrome/td td width="57" align="center"2/td /tr /tbody /table Table: *Numbers of samples in each diagnostic category*. DNA extraction: 45-80 mg of cerebellar tissue was pulverized for DNA extractions. The QIAamp DNA mini Kit (Qiagen) method was employed for tissue DNA extraction. The tissue was initially lysed using Tissue Lyser (Qiagen) and extractions were accomplished according to manufacturer's protocol. The DNA was captured in 500uL elution buffer. The concentrations were measured using Thermo Scientific's NanoDrop 1000/NanoDrop ONE. The mean yield was 128.85 uG (+/- 79.48), the mean ratio of 260/280 was 1.87 (+/- 0.105), and the mean ratio of 260/230 was 2.48 (+/-1.75). Genotyping methods: Three types of Illumina Beadarray chips were used: HumanHap650Y, Human1M-Duo, and HumanOmni5M-Quad (San Diego, California). The genotyping was done according to the manufacturer's protocol (Illumina Proprietary, Catalog # WG-901-5003, Part # 15025910 Rev.A, June 2011). Approximately, 400ng DNA was used and each DNA sample was QC tested for 260/280 ratio by nanodrop and DNA band intactness on 2% agarose gel. Briefly, the samples were whole-genome amplified, fragmented, precipitated and resuspended in appropriate hybridization buffer. Denatured samples were hybridized on prepared Bead Array Chips. After hybridization, the Bead Chip oligonucleotides were extended by a single fluorescent labeled base, which was detected by fluorescence imaging with an Illumina Bead Array Reader, iScan. Normalized bead intensity data obtained for each sample were loaded into the Illumina Genome Studio (Illumina, v.2.0.3) with cluster position files provided by Illumina, and fluorescence intensities were converted into SNP genotypes. *Microarray:* We generated RNA expression data using array technology for psychiatric subjects compared to non-psychiatric subjects as controls. We used tissues from three different brain regions i.e. hippocampus, dorsolateral prefrontal cortex (DLPFC), and dura mater for a large cohort of individuals (total number 552 subjects for hippocampus, 800 for DLPFC and 146 for dura). Total RNA was extracted from ~100 mg of tissue using the RNeasy kit (Qiagen) according to the manufacturer's protocol. RNA quality and quantity were examined using the Bioanalyzer (Agilent, Inc) and NanoDrop (Thermo Scientific, Inc), respectively. Samples with RNA integrity number (RIN) 5 were excluded. Affymetrix 3'IVT express kit protocols (Affymetrix, Inc. catalog#902416) were used to generate the Biotin labeled cRNAs. The Illumina hybridization cocktail containing 2 micrograms of biotin labeled cRNAs was hybridized to the Illumina HumanHT-12_V4 Beadchips. The chips were washed and stained using the standard Illumina protocols and reagents. The Illumina BeadChip Scanner was used to scan the arrays. Gene expression intensities were extracted using the Illumina GenomeStudioV2011.1 software. table width="481" border="1" tbody tr td width="64" align="center" strong#/strong /td td width="275" strongDiagnosis/strong /td td width="57" align="center" strongDLPFC/strong /td td width="47" align="center" strongHippo/strong /td td width="39" align="center" strongDura/strong /td /tr tr td width="64" align="center"1/td td width="275"Anxiety Disorder/td td width="57" align="center"1/td td width="47" align="center"0/td td width="39" align="center"0/td /tr tr td width="64" align="center"2/td td width="275"Autism Spectrum Disorder/td td width="57" align="center"14/td td width="47" align="center"6/td td width="39" align="center"0/td /tr tr td width="64" align="center"3/td td width="275"Bipolar Disorder/td td width="57" align="center"90/td td width="47" align="center"49/td td width="39" align="center"0/td /tr tr td width="64" align="center"4/td td width="275"Control/td td width="57" align="center"336/td td width="47" align="center"270/td td width="39" align="center"75/td /tr tr td width="64" align="center"5/td td width="275"Eating Disorder (ED)/td td width="57" align="center"2/td td width="47" align="center"1/td td width="39" align="center"0/td /tr tr td width="64" align="center"6/td td width="275"Major Depressive Disorder (MDD)/td td width="57" align="center"144/td td width="47" align="center"87/td td width="39" align="center"0/td /tr tr td width="64" align="center"7/td td width="275"Obsessive Compulsive Disorder (OCD)/td td width="57" align="center"5/td td width="47" align="center"3/td td width="39" align="center"0/td /tr tr td width="64" align="center"8/td td width="275"Post-Traumatic Stress Disorder (PTSD)/td td width="57" align="center"6/td td width="47" align="center"0/td td width="39" align="center"0/td /tr tr td width="64" align="center"9/td td width="275"Schizophrenia/td td width="57" align="center"192/td td width="47" align="center"125/td td width="39" align="center"71/td /tr tr td width="64" align="center"10/td td width="275"Other/td td width="57" align="center"5/td td width="47" align="center"6/td td width="39" align="center"0/td /tr tr td width="64" align="center"11/td td width="275"Tic Disorder/td td width="57" align="center"3/td td width="47" align="center"3/td td width="39" align="center"0/td /tr tr td width="64" align="center"12/td td width="275"Undetermined/td td width="57" align="center"1/td td width="47" align="center"1/td td width="39" align="center"0/td /tr tr td width="64" align="center"13/td td width="275"Williams Syndrome/td td width="57" align="center"2/td td width="47" align="center"1/td td width="39" align="center"0/td /tr /tbody /table Table: *Numbers of samples in each diagnostic category*. *RNA-Seq of Dorso-lateral prefrontal cortex:* All brains were collected and the dorsolateral prefrontal cortical (DLPFC) samples dissected at the HBCC, DIRP, NIMH. Dorsolateral prefrontal cortex (DLPFC) specimens were dissected from right or left hemisphere of frozen coronal slabs. The study was funded by the DIRP, NIMH under contract (#HHSN 271201400099C) with Icahn School of Medicine at Mount Sinai,1106402 One Gustave L. Levy Place, Box 3500, New York NY 10029,6574. RNA extraction, library preparation and sequencing were performed under contract at Icahn School of Medicine. The Common Mind Consortium (CMC) provided project management support. RNA isolation: Total RNA from 468 HBCC samples was isolated from approximately 100 mg homogenized tissue from each sample by TRIzol/chloroform extraction and purification with the Qiagen RNeasy kit (Cat#74106) according to manufacturer's protocol. Samples were processed in randomized batches of 12. The order of extraction for schizophrenia, bipolar, and MDD disorders and control samples was assigned randomly with respect to diagnosis and all other sample characteristics. The mean total RNA yield was 24.2 ug (+/- 9.0). The RNA Integrity Number (RIN) was determined by 4200 Agilent TapeStation System. Samples with RIN 5.5 were excluded from the study. Among the remaining samples the mean RIN was 7.5 (+/- 0.9) and the mean ratio of 260/280 was 2.0 (+/- 0.03). DLPFC RNA-Seq quantified expression data are provided for 364 samples. Data were generated, QC'd, processed and quantified as follows: RNA library preparation and sequencing: All samples submitted to the New York Genome Center for RNAseq were prepared for sequencing in randomized batches of 94. The sequencing libraries were prepared using the KAPA Stranded RNAseq Kit with RiboErase (KAPA Biosystems). rRNA was depleted from 1ug of RNA using the KAPA RiboErase protocol that is integrated into the KAPA Stranded RNAseq Kit. The insert size and DNA concentration of the sequencing library was determined on Fragment Analyzer Automated CE System (Advanced Analytical) and Quant-iT PicoGreen (ThermoFisher) respectively. table width="317" border="1" tbody tr td width="104" align="center" strongSchizophrenia/strong /td td width="67" align="center" strongBipolar/strong /td td width="68" align="center" strongControl/strong /td /tr tr td align="center"89/td td align="center"65/td td align="center"210/td /tr /tbody /table Table: *Numbers of samples in each diagnostic category*. *RNA-Seq of subgenual anterior cingulate cortex (sgACC):* All the 200 post-mortem brain samples (61 controls; 39 bipolar disorder; 46 schizophrenia; 54 major depressive disorder) were collected by the HBCC, DIRP, NIMH. RNA Extraction and Quality Assessment: Tissue from sgACC was pulverized and stored at -80°C. Total RNA was extracted from 50-80 mg of the tissue using QIAGEN RNeasy Lipid Tissue Mini Kit (QIAGEN, Cat. # 74804) with DNase treatment (QIAGEN, Cat. # 79254). The RNA Integrity Number (RIN) for each sample was assessed with high-resolution capillary electrophoresis on the Agilent Bioanalyzer 2100 (Agilent Technologies, Palo Alto, California). The concentration of RNA and their 260/280 ratio (2.1+/- 0.032 SD) were determined with NanoDrop (Thermo Scientific). RNA sequencing: Stranded RNA-Seq libraries were constructed after rRNA depletion using Ribo-Zero GOLD (Illumina). RNA sequencing was performed at National Institute of Health Intramural Sequencing Center (NISC). table width="317" border="1" tbody tr td width="104" align="center" strongSchizophrenia/strong /td td width="67" align="center" strongBipolar/strong /td td width="68" align="center" strongControl/strong /td td width="78" align="center" strongMDD/strong /td /tr tr td align="center"46/td td align="center"39/td td align="center"61/td td align="center"54/td /tr /tbody /table Table: *Numbers of samples in each diagnostic category*. *Whole Genome Sequencing:* All brains were collected and dissected at the HBCC, DIRP, NIMH. This study generates whole genome sequencing data using sequencing of DNA in the dorsolateral prefrontal cortex (DLPFC), anterior cingulate cortex (ACC) or cerebellum of 443 individuals with schizophrenia, bipolar disorder and major depressive disorder and non-psychiatric controls. The study was funded by the DIRP, NIMH under contract (#HHSN 271201400099C) with Icahn School of Medicine at Mount Sinai,1106402 One Gustave L. Levy Place, Box 3500, New York NY 10029,6574. DNA extraction, library preparation and sequencing were performed under contract at Icahn School of Medicine. The Common Mind Consortium (CMC) provided project management support. All specimens were dissected from right or left hemisphere of frozen coronal slabs. DNA Library Preparation and Sequencing: All samples submitted to the New York Genome Center for WGS were prepared for sequencing in randomized batches of 95. The sequencing libraries were prepared using the Illumina PCR-free DNA sample preparation Kit. The insert size and DNA concentration of the sequencing library was determined on Fragment Analyzer Automated CE System (Advanced Analytical) and Quant-iT PicoGreen (ThermoFisher) respectively. A quantitative PCR assay (KAPA), with primers specific to the adapter sequence, was used to determine the yield and efficiency of the adaptor ligation process. Performed on the Illumina HiSeqX with 30X coverage. table width="233" border="1" tbody tr td width="99" align="center" strongSchizophrenia/strong /td td width="67" align="center" strongBipolar/strong /td td width="68" align="center" strongControl/strong /td /tr tr td align="center" strong115/strong /td td align="center"78/td td align="center"230/td /tr /tbody /table Table: *Numbers of samples in each diagnostic category*. *ChIP-Seq:* All brains were collected and the dorsolateral prefrontal cortical (DLPFC) samples dissected at the HBCC, DIRP, NIMH. This study generates epigenetic data using sequencing of DNA after chromatin immunoprecipitation (ChIP-Seq) for marks H3K4me3 and H3K27ac in the dorsolateral prefrontal cortex (DLPFC). Dorsolateral prefrontal cortex (DLPFC) specimens were dissected from right or left hemisphere of frozen coronal slabs. The study was funded by the DIRP, NIMH under contract (#HHSN 271201400099C) with Icahn School of Medicine at Mount Sinai,1106402 One Gustave L. Levy Place, Box 3500, New York NY 10029,6574. Chromatin precipitation, library preparation and sequencing were performed under contract at Icahn School of Medicine. The Common Mind Consortium (CMC) provided project management support. Chromatin immunoprecipitation (ChIP) assays for histone marks H3K4me3 and H3K27ac were carried out using Native ChIP. Micrococcal Nuclease (MNase) (Sigma, N3755) treatment was used to digest chromatin into mononucleosomes. The following antibodies were used for chromatin pull-down: anti-H3K4me3 (Cell Signaling, Cat# 9751BC, lot 7) and anti-H3K27ac (Active Motif, Cat# 39133, Lot # 31814008). Histone modification-enriched genomic DNA fragments were recovered using Protein A/G magnetic beads (Thermo Scientific, 88803-88938 or Millipore 16-663), and then washed, eluted, and treated with RNAse A and proteinase K. Final ChIP DNA products were isolated using phenol-chloroform extraction followed by ethanol precipitation. The efficiency of each ChIP assay was validated using Qubit concentration measurement and qPCR for positive (GRIN2B, DARPP32) and negative (HBB) control genomic regions. Only ChIP assays that passed quality control were further processed for library preparation and sequencing; this included ChIP DNA that was not detectable on Qubit but showed a good signal and expected enrichment patterns in qPCR. table width="291" border="1" tbody tr td width="64" align="center" strong/strong /td td colspan="3" width="153" align="center" strongHISTONE_MARK/strong /td td width="73" align="center" strong/strong /td /tr tr td width="64" align="center" /td td colspan="2" width="77" align="center" strongH3K27ac/strong /td td width="77" align="center" strongH3K4me3/strong /td td width="73" align="center" strongInput/strong /td /tr tr td width="64" strongBipolar/strong /td td width="73" align="center"56/td td colspan="2" width="80" align="center"4/td td width="73" align="center" strong7/strong /td /tr tr td width="64" strongControl/strong /td td width="73" align="center"158/td td colspan="2" width="80" align="center"11/td td width="73" align="center"24/td /tr tr td width="64" strongSchizophrenia/strong /td td width="73" align="center"79/td td colspan="2" width="80" align="center"11/td td width="73" align="center"12/td /tr /tbody /table Table: *Numbers of individuals in each assay grouped by histone mark or input*.

Eligibility

1 itemgroup 2 items

pht005196.v3.p2

1 itemgroup 7 items

pht005193.v2.p2

1 itemgroup 2 items

pht005194.v3.p2

1 itemgroup 2 items
- 9/20/21 - 1 form, 8 itemgroups, 70 items, 1 language
Itemgroups: Administrative Data, Demographic factors, Health status, Prior Treatment, Symptom Burden, Functioning, Recovery Speed and Health Sustainability, Other
ICHOM Depression and Anxiety data collection Version 2.3.2 Revised: August 10th, 2018 International Consortium for Health Outcomes Measurement (ICHOM), Source: http://www.ichom.org/ Notice: This work was conducted using resources from ICHOM, the International Consortium for Health Outcomes Measurement (www.ICHOM.org). The content is solely the responsibility of the authors and does not necessarily represent the official views of ICHOM. For Depression and Anxiety, the following conditions and treatment approaches (or interventions) are covered by our Standard Set. This document contains the Baseline - Patient-reported Form. It has to be filled in at Baseline(Treatment begin). Condition: Depression: Major Depressive Disorder | Dysthymia | Depressive Adaptive/Adjustment Disorder | Depressive Disorder - NOS Anxiety: Generalized Anxiety Disorder | Phobic Disorder | Agoraphobia | Post-Traumatic Stress Disorder | Panic Disorder | Obsessive-Compulsive Disorder Treatment Approaches : Psychopharmacotherapy | Psychotherapy | Lifestyle Interventions | Self-Guided Help | Other Forms of Therapy Collecting Clinician and Patient-Reported Outcome Measures: PHQ-9 (Patient Health Questionnaire). https://www.phqscreeners.com/ Pfizer: All PHQ, GAD-7 screeners and translations are downloadable from this website and no permission is required to reproduce, translate, display or distribute them. GAD-7 (Generalized Anxiety Disorder). https://www.phqscreeners.com/ Pfizer: All PHQ, GAD-7 screeners and translations are downloadable from this website and no permission is required to reproduce, translate, display or distribute them. (and all other GAD or PHQ screeners); Pfizer owner, authors: Drs. Spitzer, Williams and Kroenke SPIN (Social Phobia Inventory ), MIA (Mobility Inventory for Agoraphobia), IES-R (Impact of Event Scale - Revised for Post-traumatic Stress Disorder), PDSS-SR (Panic Disorder Severity Scale), OCI-R (Obsessive-Compulsive Inventory). As permission for use has to be obtained for all of these questionnaires from the copyright holder, only the total score will be included in this version of the standard set. WHODAS 2.0 (World Health Organization Disability Assessment Schedule 2.0). As there is a license needed for use of this questionnaire, only the total score will be included in this version oft he standard set. MOS-SSS (Medical Outcomes Study: Social Support Survey). There is no license or permission needed for use. https://www.rand.org/health-care/surveys_tools/mos/social-support.html This Standard set of ICHOM was supported by the Douglas mental health university institute, Charité Universitätsmedizin Berlin, Stichting benchmark GGC. Publication: Obbarius A, van Maasakkers L, Baer L, et al. Standardization of health outcomes assessment for depression and anxiety: recommendations from the ICHOM Depression and Anxiety Working Group. Qual Life Res. 2017;26(12):3211–3225. doi:10.1007/s11136-017-1659-5 For this version of the standard set, semantic annotation with UMLS CUIs has been added.
- 8/12/20 - 1 form, 7 itemgroups, 50 items, 1 language
Itemgroups: Explanation, During THE PAST WEEK, did you suffer from:, During THE PAST WEEK, did you suffer from:, During THE PAST WEEK, did you feel:, During THE PAST WEEK, did you feel:, During THE PAST WEEK, did you:, During THE PAST WEEK:
Terluin, B.. (2012). Four-Dimensional Symptom Questionnaire (4DSQ) . Measurement Instrument Database for the Social Science. Retrieved 12.08.2020 from www.midss.ie Key references: Terluin B, Van Rhenen W, Schaufeli WB, De Haan M. The Four-Dimensional Symptom Questionnaire (4DSQ): measuring distress and other mental health problems in a working population. Work and Stress 2004; 18(3): 187-207. Terluin B, Van Marwijk HWJ, Adèr HJ, De Vet HCW, Penninx BWJH, Hermens MLM, Van Boeijen CA, Van Balkom AJLM, Van der Klink JJL, Stalman WAB. The Four-Dimensional Symptom Questionnaire (4DSQ): a validation study of a multidimensional self-report questionnaire to assess distress, depression, anxiety and somatization. BMC Psychiatry 2006; 6:34. Terluin B, Brouwers EPM, van Marwijk HWJ, Verhaak PFM, van der Horst HE. Detecting depressive and anxiety disorders in distressed patients in primary care; comparative diagnostic accuracy of the Four-Dimensional Symptom Questionnaire (4DSQ) and the Hospital Anxiety and Depression Scale (HADS). BMC Fam Pract 2009; 10:58. Primary use / Purpose: The 4DSQ is a self-report questionnaire to assess distress, depression, anxiety and somatization. It is mainly used in primary care. The 4DSQ helps to differentiate between normal distress and psychiatric disorder. Background: Many health care problems in primary care are stress-related (distress) and do not represent true psychiatric disorder (irrespective of whether DSM-IV criteria for depressive or anxiety disorders are fulfilled). Indiscriminate application of DSM-IV criteria in the primary care setting produces many false positive diagnoses confusing patients and misleading professionals. In health care practice the 4DSQ can be used to: - help patients acknowledge mental health issues when presenting with physical complaints, - assess the overall severity of the mental health problems, - detect depressive and anxiety disorders severe enough to require specific treatment (antidepressants or cognitive behavioral therapy), - monitor patients' progress under treatment. Psychometrics: The 4DSQ has been extensively tested for reliability and validity. Reliability is high (coefficients generally >.80). Factorial, critirion and concurrant validity has been confirmed. Web link to tool: Four-Dimensional Symptom Questionnaire (4DSQ) Other Information: The 4DSQ is free for non-commercial use. Available language versions: English, Dutch, French, German, Polish, Turkish Digital Object Identifier (DOI): http://dx.doi.org/10.13072/midss.167 Scoring: "no" = score 0 "sometimes" = score 1 "regularly" or more often = score 2 Distress: sum the items 17, 19, 20, 22, 25, 26, 29, 31, 32, 36, 37, 38, 39, 41, 47, 48 Interpretation: moderately elevated if > 10, strongly elevated if > 20 Depression: sum the items 28, 30, 33, 34, 35, 46 Interpretation: moderately elevated if > 2, strongly elevated if > 5 Anxiety: sum the items 18, 21, 23, 24, 27, 40, 42, 43, 44, 45, 49, 50 moderately elevated if > 8, strongly elevated if > 12 Somatisation: sum the items 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 moderately elevated if > 10, strongly elevated if > 20
- 8/5/20 - 1 form, 2 itemgroups, 18 items, 1 language
Itemgroups: General Information, The Penn State Worry Questionnaire (PSWQ)
Meyer, T. J., Miller, M. L., Metzger, R. L., Borkovec, T. D. (1990). The Penn State Worry Questionnaire (PSWQ). Measurement Instrument Database for the Social Science. Retrieved 05.08.2020, from www.midss.ie Key references: Original article: Meyer, T. J., Miller, M. L., Metzger, R. L., & Borkovec, T. D. (1990). Development and validation of the penn state worry questionnaire. Behavior Research and Therapy, 28, 487-495. Brown, T.A. Confirmatory factor analysis of the Penn State Worry Questionnaire: Multiple factors or method effects? Behavior Research and Therapy (2003) 41, 1411-14226. Fresco, D.M., et. al. ( 2003) Using the Penn State Worry Questionnaire to identify individuals with Generalized Anxiety Disorder: a receiver operating characteristic analysis. Journal of Behavior Therapy and Experimental Psychiatry. 34, 283-291. Gillis, M.M., Haaga, D.A. and Ford, G.T. (1995) Normative values for the Beck Anxiety Inventory, Fear Questionnaire, Penn State Worry Questionnaire, and Social Phobia and Anxiety Inventory. Psychological Assessment, 7, 450-455. Primary use / Purpose: The Penn State Worry Questionnaire (PSWQ) is a 16-item questionnaire that aims to measure the trait of worry, using Likert rating from 1 (not at all typical of me) to 5 (very typical of me). Research suggests that the instrument has a strong ability to differentiate patients with generalized anxiety disorder (GAD) from other anxiety disorders. Background: Worry is regarded as a dominant feature of GAD. Since its development in 1990, the PSWQ has become a widely used self-report tool for pathological worry and GAD. The PSWQ attempts to measure the excessiveness, generality, and uncontrollable dimensions of worry. Psychometrics: The PSWQ has shown to possess high internal consistency and good test-retest reliability (Meyer et al., 1990). Digital Object Identifier (DOI): http://dx.doi.org/10.13072/midss.158 Scoring the PSWQ In scoring the PSWQ, a value of 1, 2, 3, 4, and 5 is assigned to a response depending upon whether the item is worded positively or negatively. The total score of the scale ranges from 16 to 80. Items 1, 3, 8, 10, 11 are reverse scored as follows: • Very typical of me = 1 (circled 5 on the sheet) • Circled 4 on the sheet = 2 • Circled 3 on the sheet = 3 • Circled 2 on the sheet = 4 • Not at all typical of me = 5 (circled 1 on the sheet) For items 2, 4, 5, 6, 7, 9, 12, 13, 14, 15, 16 the scoring is: • Not at all typical of me = 1 • Ratings of 2, 3, and 4 are not transformed • Very typical of me = 5

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial